Group 1 - U.S. stock futures are higher, with Dow futures gaining around 50 points [1] - Tilray Brands Inc announced a one-for-10 reverse stock split, effective December 1 [1] - Tilray shares fell sharply by 15% to $0.88 in pre-market trading [2] Group 2 - Inventiva ADR fell 7.4% to $4.26 in pre-market trading after a previous gain [4] - Anglogold Ashanti PLC dipped 5.5% to $83.97 in pre-market trading after a gain of over 5% [4] - Lexicon Pharmaceuticals Inc fell 5% to $1.36 in pre-market trading [4] - SuperX AI Technology Ltd fell 3.9% to $26.00 in pre-market trading after a significant previous jump of 23% [4] - Palisade Bio Inc declined 3.6% to $2.15 in pre-market trading [4] - Gold Fields Ltd fell 3.4% to $41.76 in pre-market trading after a gain of 6% [4] - Abacus Global Management Inc fell 3.2% to $6.33 in pre-market trading after reporting better-than-expected third-quarter results and announcing a $10 million buyback [4]

Core Points - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and announced the results of its Combined Shareholders' Meeting held on November 27, 2025 [1][10]. Voting Results - All resolutions submitted to the shareholders were adopted, except for resolution 5, which was negatively recommended by the Board of Directors. This resolution aimed to empower the Board to decide on share capital increases for a company savings plan [3][4]. - The Combined Shareholders' Meeting had a total of 441 shareholders represented, with a total of 119,608,674 votes cast, achieving a quorum of 56.432% [5]. - In the ordinary resolutions, the votes for resolutions ranged from 89.7% to 99.9% in favor, with the highest support for resolution 6 [6][7]. - In the extraordinary resolutions, resolution 4 was adopted with 89.9% in favor, while resolution 5 was rejected with only 41.6% support [8][9]. Company Overview - Inventiva is publicly listed on Euronext Paris and Nasdaq, focusing on the research and development of oral small molecule therapies for MASH and other diseases with significant unmet medical needs. The company is currently evaluating lanifibranor in a pivotal Phase 3 clinical trial [10][11].

Core Viewpoint - The press release provides information regarding the stabilization activities related to the recent public offering of Inventiva in the United States, which involved the issuance of 38,961,038 American Depositary Shares (ADSs) and an additional 5,844,155 ADSs purchased by underwriters [1][2]. Group 1: Offering Details - The public offering consisted of 38,961,038 ADSs, with an additional 5,844,155 ADSs purchased by underwriters [1][2]. - The offer price for each ADS was set at $3.85 [2]. - The stabilization activities were conducted by Piper Sandler, which acted as the stabilization agent [2]. Group 2: Stabilization Activities - The stabilization period commenced on November 13, 2025, and concluded on November 17, 2025 [2]. - On November 13, 2025, Piper Sandler executed a buy transaction for 20,700 shares at an average price of $3.6933, with a total transaction amount of $76,451.31 [2].

Core Viewpoint - Inventiva, a clinical-stage biopharmaceutical company, reported its financial results for the first nine months of 2025, highlighting its cash position, revenue generation, and operational expenditures, while also discussing future financing and operational sustainability [1]. Financial Position - As of September 30, 2025, the company's cash and cash equivalents were €97.6 million, a slight increase from €96.6 million at the end of 2024 [2]. - The company also held €24.7 million in short-term deposits as of the same date [10]. Cash Flow Analysis - Net cash used in operating activities for the first nine months of 2025 was (€76.3) million, a 20% increase from (€63.7) million in the same period of 2024, attributed to working capital changes and the impact of a pipeline prioritization plan [3]. - Net cash used in investing activities was (€25.0) million, a significant decrease from €8.9 million generated in the same period of 2024, primarily due to variations in short-term deposits [4]. - Net cash generated from financing activities amounted to €103.4 million, up from €41.9 million in the same period of 2024, mainly from a structured financing settlement [5]. Revenue Generation - Revenues for the first nine months of 2025 totaled €4.5 million, compared to no revenue in the same period of 2024 [9]. - The revenue primarily consisted of a €10 million milestone payment from Chia Tai Tianqing Pharmaceutical Group and €4.3 million from credit notes under a license agreement [11]. Future Outlook - The company estimates that its current cash position, along with net proceeds from a recent public offering, will sustain operations until the end of the first quarter of 2027 [8]. - The company anticipates potential additional proceeds from the exercise of Tranche 3 warrants, which could extend its financial runway until mid-third quarter of 2027 [8]. Upcoming Events - Key upcoming milestones include topline results of the NATiV3 trial expected in the second half of 2026 [12]. - A combined general meeting of shareholders is scheduled for November 27, 2025 [13]. - Participation in the MASH-TAG scientific conference is set for January 7-11, 2026 [14].

Core Points - Inventiva, a clinical-stage biopharmaceutical company, announced the full exercise of the underwriters' option in its public offering, resulting in a total of 44,805,193 American Depositary Shares (ADSs) issued, generating gross proceeds of approximately $172.5 million (€149.0 million) [1][2] - The offering price was set at $3.85 per ADS, which corresponds to €3.33 per ordinary share, reflecting a discount of 0.89% from the volume-weighted average price [4] - The net proceeds from the offering will be approximately $161.2 million (€139.3 million) after deducting underwriting fees and expenses, and these funds will be allocated on a pro rata basis to the intended uses identified in the base offering [2][3] Company Overview - Inventiva focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and is currently evaluating lanifibranor in a pivotal Phase 3 clinical trial [8] - The company is publicly listed on both Euronext Paris and the Nasdaq Global Market under the ticker symbol "IVA" [4][9]

Core Points - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) [3] - The trading of Inventiva's ordinary shares on Euronext Paris resumed on November 13, 2025, at 4:30 p.m. CET after a halt for a public offering in the United States [1][2] Company Overview - Inventiva is engaged in the research and development of oral small molecule therapies specifically targeting MASH, a progressive chronic liver disease [3] - The company is currently conducting the NATiV3 pivotal Phase 3 clinical trial for lanifibranor, a novel pan-PPAR agonist aimed at treating adult patients with MASH [3] Trading Information - Trading of the company's ordinary shares was halted at its request on November 13, 2025, at 9:00 a.m. CET to facilitate the public offering of new American Depositary Shares [2] - The offering involved new American Depositary Shares, each representing one new ordinary share with a nominal value of €0.01 [2]

Core Viewpoint - Inventiva, a clinical-stage biopharmaceutical company, has announced the pricing of its public offering of 38,961,038 new American Depositary Shares (ADSs) at $3.85 per ADS, aiming to raise approximately $140.1 million in net proceeds to fund its clinical trials and working capital needs [1][8]. Offering Details - The offering price of $3.85 per ADS corresponds to €3.33 per ordinary share, reflecting a discount of 0.89% from the volume-weighted average price on Euronext [2]. - The offering is underwritten by Leerink Partners and Piper Sandler, with Namsen Capital serving as the Equity Capital Markets Advisor [3]. - The company has granted underwriters a 30-day option to purchase up to 5,844,155 additional ADSs, representing 15% of the ADSs sold in the offering [6]. Financial Proceeds and Use - The estimated net proceeds from the offering are approximately $140.1 million (€121.0 million), which could increase to $161.2 million (€139.3 million) if the underwriters' option is fully exercised [8]. - The company plans to allocate approximately 80% of the net proceeds to fund the continuation of its NATiV3 Phase 3 clinical trial and commercialization activities, while the remaining 20% will be used for working capital and general corporate purposes [9][10]. Current Financial Position - As of September 30, 2025, Inventiva had cash and cash equivalents of €97.61 million and short-term deposits of €24.71 million, which are projected to be insufficient to meet its obligations over the next 12 months without the proceeds from the offering [10][11]. Shareholder Impact - Samsara BioCapital L.P. has subscribed to 5,194,805 ADSs for approximately $19.99 million, increasing its ownership from 5.7% to 7.3% post-offering [12]. - The company's board members and executive officers are subject to a 90-day lock-up period following the offering [13]. Market Trading - The ordinary shares underlying the ADSs will be admitted to trading on Euronext under the same ISIN code as existing shares, with trading on Euronext suspended until the opening of trading on Nasdaq [29][30].

Core Points - Inventiva, a clinical-stage biopharmaceutical company, announced a temporary halt in trading of its ordinary shares on Euronext Paris due to a public offering of new American Depositary Shares (ADSs) in the United States [1][2] - The trading halt is expected to last until approximately 3:30 p.m. CET on November 13, 2025, when trading is anticipated to resume [2] - Inventiva is focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and is currently evaluating lanifibranor in a pivotal Phase 3 clinical trial [3] Company Overview - Inventiva is listed on Euronext Paris and the Nasdaq Global Market, focusing on oral small molecule therapies for MASH [3][4] - The company is conducting research on lanifibranor, a novel pan-PPAR agonist, aimed at treating adult patients with MASH, a progressive chronic liver disease [3]

Core Viewpoint - Inventiva plans to offer approximately $125 million (about €108 million) of new American Depositary Shares (ADSs) in an underwritten public offering in the United States, aimed at funding its clinical trials and commercialization activities [1][2]. Group 1: Offering Details - The offering will consist of new ADSs, each representing one ordinary share of the company with a nominal value of €0.01 [1]. - The net proceeds from the offering will primarily be used to fund the continuation of the NATiV3 Phase 3 clinical trial and other corporate purposes [2]. - The offering is subject to market conditions, and the final terms will be determined through a book-building process [4]. Group 2: Financial Information - As of September 30, 2025, the company had cash and cash equivalents of €97.6 million and short-term deposits of €24.7 million, which are projected to finance operations until the end of Q3 2026 [10]. - The company estimates that its current cash resources will not be sufficient to meet its obligations over the next 12 months [10]. Group 3: Regulatory and Market Considerations - The offering will be conducted without shareholders' preferential subscription rights, in accordance with resolutions from the company's general meeting [3]. - The ordinary shares represented by ADSs will be subject to an application for admission to trading on Euronext under the same ISIN code as existing shares [8]. - The trading of the company's ordinary shares on Euronext is expected to be suspended on November 13, 2025, until the opening of trading of the ADSs on Nasdaq [9]. Group 4: Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) [16]. - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for MASH treatment [16].

Market Overview - U.S. stock futures were higher, with Dow futures gaining over 100 points on Thursday [1] Company-Specific Movements - Satellogic Inc. (NASDAQ:SATL) shares fell 13.1% to $3.60 in pre-market trading following a proposed public offering [1] - American Battery Technology Company (NASDAQ:ABAT) shares dipped 23.9% to $6.81 after the DOE terminated its grant [3] - Hyperfine, Inc. (NASDAQ:HYPR) shares decreased 14.1% to $1.89 after reporting preliminary third-quarter revenue results below estimates and announcing a proposed public offering [3] - Omeros Corporation (NASDAQ:OMER) shares declined 9.2% to $9.45 after a significant 154% jump on Wednesday due to Novo Nordisk acquiring its global rights to Zaltenibart [3] - Hewlett Packard Enterprise Company (NYSE:HPE) tumbled 8.6% to $22.85 despite reporting record revenue driven by AI demand, as restructuring costs compressed profit margins [3] - NIO Inc. (NYSE:NIO) fell 8.5% to $6.24 in pre-market trading [3] - Inventiva S.A. (NASDAQ:IVA) declined 7.5% to $5.06 after a 10% gain on Wednesday [3] - Bitfarms Ltd. (NASDAQ:BITF) fell 4.6% to $6.17 after announcing a $300 million convertible senior notes offering [3] - Rigetti Computing, Inc. (NASDAQ:RGTI) shares fell 4.8% to $53.66 amid concerns over leadership commitment after the CEO sold all shares following an options exercise [3] - Datavault AI Inc. (NASDAQ:DVLT) slipped 4.8% to $2.00 in pre-market trading [3]